Introduction

Asthma is a multiphenotypic disease, and therapeutic managenment in patients with severe asthma is particulary difficult, with conventional treatment of severe asthma showing poor efficacy.

Aim

To analyse forced expiratory volume in 1 s (FEV1) following the adminstration of omalizumab.

Material and methods

Six patinents (mean age: 50 ±12.6) with severe, uncontrolled asthma according to the GINA guidelines were enrolled in the study.

Results

Treatment with omalizumab increased in all subjects FEV1 by 17.28 ±13.4% after months and 18.57 ±13.4% after 12 months of treatment.

Conclusions

These results provides further evidence that therapy with omalizumab improves spiromtric parameters in severe asthma.